Physicians' Academy for Cardiovascular Education

SHARP study

Slides (presentation) - May 18, 2011

The Study of Heart and Renal Protection (SHARP)

concluded that around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels.

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Summary of major findings:
  • Taking the combination of ezetimibe and simvastatin long-term reduced the risk of heart attacks, strokes and operations to open blocked arteries by about one quarter in people with chronic kidney disease, irrespective of the severity of their disease
  • This combination treatment reduced risk safely, and may be particularly good for kidney patients as it avoids the possibility of side-effects with high statin doses
  • There was no support for previous concerns with ezetimibe about possible adverse effects on cancer, and no evidence of an increased risk of muscle or liver problems
For more information visit the SHARP website


SHARP: Rationale
SHARP: Eligibility
SHARP: Assessment of LDL-lowering
SHARP: Baseline characteristics
SHARP: Main outcomes
SHARP: Major Atherosclerotic Events
CTT: Effects on Major Atherosclerotic Events
CTT: Effects on Major Atherosclerotic Events
SHARP: Major Vascular Events
SHARP: Effects in subgroups
SHARP: Major Atherosclerotic Events
SHARP: Cause-specific mortality
SHARP: Renal outcomes
SHARP: Safety
SHARP: Conclusions

Share this page with your colleagues and friends: